- Centogene NV CNTG and Twist Bioscience Corporation TWST have signed a contract to develop and commercialize custom assay kits for rare diseases.
- The financial details of the deal were not disclosed.
- Related: Twist Bioscience, Boehringer Ingelheim Joins Forces For Antibody Research Programs.
- The product offering will combine Centogene's Bio/Databank with Twist Bioscience's library preparation and target enrichment capabilities to deliver multiple rare disease diagnosis and analysis assays.
- Price Action: CNTG stock is up 0.39% at $10.30, while TWST stock is down 2.68% at $96.69 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
